Two-year course of depressive and anxiety disorders: Results from the Netherlands Study of Depression and Anxiety (NESDA)  by Penninx, Brenda W.J.H. et al.
Journal of Affective Disorders 133 (2011) 76–85
Contents lists available at ScienceDirect
Journal of Affective Disorders
j ourna l homepage: www.e lsev ie r.com/ locate / j adResearch report
Two-year course of depressive and anxiety disorders: Results from the
Netherlands Study of Depression and Anxiety (NESDA)
Brenda W.J.H. Penninx a,b,c,⁎,1, Willem A. Nolen b,1, Femke Lamers a,1, Frans G. Zitman c,1,
Johannes H. Smit a,1, Philip Spinhoven d,1, Pim Cuijpers e,1, Peter J. de Jong f,1,
Harm W.J. van Marwijk g,1, Klaas van der Meer h,1, Peter Verhaak i,1, Miranda G.H. Laurant j,1,
Ron de Graaf k,1, Witte J. Hoogendijk a,1, Nic van der Wee c,1, Johan Ormel b,1,
Richard van Dyck a,1, Aartjan T.F. Beekman a,1
a Department of Psychiatry/EMGO Institute for Health and Care Research/Neuroscience Campus Amsterdam, VU University Medical Center, Amsterdam, The Netherlands
b Department of Psychiatry, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
c Department of Psychiatry, Leiden University Medical Center, Leiden, The Netherlands
d Department of Clinical Psychology, Leiden University, Leiden, The Netherlands
e Department of Clinical Psychology, VU University, Amsterdam, The Netherlands
f Department of Clinical Psychology, University of Groningen, Groningen, The Netherlands
g Department of General Practice, VU University Medical Center, Amsterdam, The Netherlands
h Department of General Practice, University Medical Center Groningen, Groningen, The Netherlands
i Netherlands Institute for Health Services Research, Utrecht, The Netherlands
j Scientiﬁc Institute for Quality of Healthcare, Radboud University Medical Center, Nijmegen, The Netherlands
k Netherlands Institute of Mental Health and Addiction, Utrecht, The Netherlandsa r t i c l e i n f o⁎ Corresponding author at: Department of Psychiat
7885437; fax: +31 20 7885664.
E-mail address: b.penninx@vumc.nl (B.W.J.H. Penn
1 The NESDA research consortium.
0165-0327/© 2011 Elsevier B.V. Open access under the E
doi:10.1016/j.jad.2011.03.027a b s t r a c tArticle history:
Received 9 December 2010
Received in revised form 12 March 2011
Accepted 12 March 2011
Available online 14 April 2011Background: Whether course trajectories of depressive and anxiety disorders are different,
remains an important question for clinical practice and informs future psychiatric nosology.
This longitudinal study compares depressive and anxiety disorders in terms of diagnostic and
symptom course trajectories, and examines clinical prognostic factors.
Methods: Data are from 1209 depressive and/or anxiety patients residing in primary and
specialized care settings, participating in the Netherlands Study of Depression and Anxiety.
Diagnostic and Life Chart Interviews provided 2-year course information.
Results: Course was more favorable for pure depression (n=267, median episode duration=6 -
months, 24.5% chronic) than for pure anxiety (n=487, median duration=16months, 41.9%
chronic). Worst course was observed in the comorbid depression–anxiety group (n=455, median
duration N24 months, 56.8% chronic). Independent predictors of poor diagnostic and symptom
trajectory outcomes were severity and duration of index episode, comorbid depression–anxiety,
earlier onset age and older age.With only these factors a reasonable discriminative ability (C-statistic
0.72–0.77) was reached in predicting 2-year prognosis.
Limitation: Depression and anxiety cases concern prevalent – not incident – cases. This, however,
reflects the actual patient population in primary and specialized care settings.
Conclusions: Their differential course trajectory justifies separate consideration of pure depression,
pure anxiety and comorbid anxiety–depression in clinical practice and psychiatric nosology.
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Depressive and anxiety disorders have an enormous
impact on public health for a large part because both
disorders often present a chronic-intermittent course and
consequently have sustained impact over the life-cycle. As
from Kraepelin's time, a disorder's prognosis has been an
important criterion to validate clinical entities: when natu-
ralistic course differs across disorders, their distinction could
be useful in clinical practice and psychiatric nosology. For
depressive disorders, longitudinal, naturalistic cohort studies
indicate that themedian duration of episodes ranges between
3 and 6 months, whereas approximately 20% of episodes
becomes chronic (Keller et al., 1992; Ormel et al., 1993;
Spijker et al., 2002). In anxiety disorders the few large-scale
prognostic studies indicate an at least similarly poor or even
worse course trajectory. Two reviews estimated that the
course of panic disorder shows little to no improvement in
36–40% of the subjects (Keller and Hanks, 1993; Pollack and
Otto, 1997). The HARP study showed that only 35% of the
patients with social phobia recovered over 10 years, while the
recurrence rate after recovery was 34% (Keller, 2006).
Although these results depict anxiety disorders as insidious
with a less favorable course compared to depressive disor-
ders, comparison is hampered since few prior studies directly
compared the course of depressive and anxiety disorders
within the same study design andwith the same instruments.
Given the well-documented high levels of comorbidity, and
the effect this may have on prognosis (Bruce et al., 2005;
Merikangas et al., 2003; Ormel et al., 1993), any study
comparing the prognosis of anxiety and depression should
consider those with comorbid conditions separately to avoid
confounding results. This issue has not always been ade-
quately addressed.
In addition, proper insight into clinical determinants of the
naturalistic course of depressive and anxiety disorders is of
great importance for a better scientiﬁc and clinical under-
standing of these disorders. Most prognostic studies have
found that basic clinical factors, such as severity and duration
of the index episode are among the most consistent and
strongest predictors (Spijker et al., 2002, 2004; Vuorilehto
et al., 2009). Also, speciﬁc type of disorder may provide
important course information since it, for instance, has been
reported that the course is more favorable for panic disorder
than for social phobia (Yonkers et al., 2003). For socio-
demographics such as age, female gender and low education,
which are all conﬁrmed determinants of the onset of anxiety
and depressive disorders (Bijl et al., 1998a; Kessler et al.,
1994; Seedat et al., 2009), the role in course prediction has
been less consistent (Ramsawh et al., 2009; Spijker et al.,
2002; Yonkers et al., 2003). This may indicate that once the
disorder has become established, not the factors predicting
the onset, but the clinical features of the disorder itself are
most important for prognosis. This study examines the 2-year
course in a large cohort of depressed and/or anxious persons
from both primary care and specialized mental health care
and directly compares course outcome between subjects with
pure depression, pure anxiety and comorbid depression–
anxiety. In addition, it will be determined to what extent
course outcome is dependent on basic demographic and
clinical factors.2. Methods
2.1. Study sample
The Netherlands Study of Depression and Anxiety
(NESDA) is an ongoing cohort study designed to investigate
the course and consequences of depressive and anxiety
disorders. A total of 2981 persons aged 18 through 65 years
were included, consisting of healthy controls, persons with a
prior history, and persons with a current depressive and/or
anxiety disorder. To represent the entire range of settings and
stages of psychopathology in which patients in the natural-
istic (clinical) reality are seen, depressed or anxious subjects
were recruited in three Dutch regions in three settings: the
community, primary care, and secondary care. Community-
based subjects with depressive or anxiety disorders were
previously identiﬁed in two population-based studies (Nem-
esis (Bijl et al., 1998b) and Ariadne (Landman-Peeters et al.,
2005)). Primary care patients were identiﬁed through a 3-
stage screening procedure (involving the K10 and the CIDI
short form (Donker et al., 2010)), among patients of 65
General Practitioners consulting for any reason in a 4-month
period. In secondary care, patients were recruited when
newly enrolled for a depressive or anxiety disorder at one of
the 17 participating mental health organization locations.
General exclusion criteria were a primary diagnosis of
psychotic, obsessive compulsive, bipolar or severe addiction
disorder and not being ﬂuent in Dutch. A detailed description
of the NESDA design and sampling procedures is elsewhere
(Penninx et al., 2008). We previously showed that non-
response was not so much related to mental health status but
was slightly higher among younger and male respondents
(Penninx et al., 2008; van der Veen et al., 2009). The baseline
assessment included assessment of demographic and per-
sonal characteristics, a standardized diagnostic psychiatric
interview and a medical assessment. The research protocol
was approved by the Ethical Committee of participating
universities and all respondents provided written informed
consent. After two years, a face-to-face follow-up assessment
was conducted with a response of 87.1% (n=2596). Non-
response was signiﬁcantly higher among those with younger
age, lower education, non-North European ancestry and
depressive disorder, but was not associated with gender or
anxiety disorder (Lamers et al., in press).
The presence of depressive (major depressive disorder,
and dysthymia) or anxiety (panic disorder, social phobia,
generalized anxiety disorder, and agoraphobia) disorders was
established using the DSM-IV based Composite Interview
Diagnostic Instrument (CIDI, version 2.1), a highly reliable
and valid instrument for assessing depressive and anxiety
disorders (Wittchen, 1994). For the present analysis, only
subjects whowere symptomatic in themonth before baseline
were included. Consequently, the sample was restricted to
the 1456 subjects with a 6-month depressive or anxiety
diagnosis who conﬁrmed symptoms in the month prior to
baseline at either the CIDI recency questions or the Life Chart
Interview (see below). Of these, 1209 (83.0%) participated in
the 2-year follow-up (median in-between time=24 months)
and all had complete data on the central outcome indicators
(CIDI and LCA): 267 (22.1%) with a pure depressive disorder
(‘Dep’), 487 (40.2%) with a pure anxiety disorder (‘Anx’) and
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(‘Comorbid’) at baseline.
2.2. Course of depressive and anxiety disorders
Course was determined using two sources of data
collected during the 2-year follow-up assessment: 1) the
CIDI interview and the 2) Life Chart Interview (LCI). The CIDI
interview determined the presence of DSM-IV classiﬁed
depressive and anxiety disorders during the time between
baseline assessment and 2-year follow-up. Organic exclusion
rules were used in deﬁning diagnoses, and hierarchy-free
diagnoses. For all persons with detected depressive or anxiety
symptoms in the CIDI interview, the LCI was conducted by
trained and supervised clinical research staff. Using a calendar
method, life events are recalled to refresh memory after
which the presence of depressive and anxiety symptoms –
separately – at each month during this 2-year period was
determined. In addition, for each month with reported
symptoms, severity was assessed ranging from no or minimal
severity, mild, moderate, to severe, or very severe. Earlier
studies have described the method behind the LCI in detail
(Lyketsos et al., 1994) and its methodology has shown high
validity and reliability (Warshaw et al., 1994). Symptoms on
LCI were only considered to be present when at least of mild
severity. Using both the CIDI and LCI, the following course
indicators were created:
(Time to) remission of index disorder was deﬁned based on
LCA as the occurrence and the ﬁrst time-point at which no
symptoms of the index disorder were reported for three
consecutive months. For instance, remission of an anxiety
disorder was considered present when no anxiety symptoms
at all existed for 3 consecutive months during follow-up, and
likewise a comorbid conditionwas considered remittedwhen
no symptoms at all of both anxiety or depression existed for 3
consecutive months. This 3-month criterion is in line with
that used before (Spijker et al., 2002) and was uniformly
applied across all disorders to allow comparison of outcomes.
No distinction was made between remission and recovery
(Frank et al., 1991) because the data did not allow for such
precision. Among subjects with a remission, the recurrence
and time to recurrence of index disorder was assessed using
LCA information and deﬁned as the re-occurrence of
symptoms with at least mild severity for at least one month
under the condition that also the CIDI interview conﬁrmed
the presence of a depressive or anxiety disorder during
follow-up.
Psychiatric status after 2 years was based on the presence
of CIDI DSM-IV diagnosed anxiety or depressive disorders (6-
month recency) at the time of the 2-year follow-up.
Clinical course trajectory of index disorder was deﬁned by
categorizing persons into four categories on the basis of both
their depressive and anxiety symptoms over time. As done
before (Beekman et al., 2002), distinction was made between:
a) early sustained remission deﬁned as remission of index
disorder(s) within six months without recurrence of any
symptoms during follow-up, b) late sustained remission
deﬁned as remission after six months without recurrence of
any symptoms, c) remission with recurrence: those with
remission but later recurrence of depressive and anxiety
symptoms, and d) chronic course: those without remissionbut enduring anxiety and/or depression symptoms of at least
mild severity during the entire follow-up period.
Duration of symptoms during follow-up was calculated
using LCA data as the percentage of time during follow-up
with symptoms of at least mild severity. Duration of
symptoms was calculated as (number of affected months/
total number of follow-up months)⁎100%, and ranged from
0% (no symptoms during follow-up) to 100% (symptoms
during entire follow-up).
2.3. Determinants of 2-year course
2.3.1. Sociodemographics
Information was included on age, gender and years of
education.
2.3.2. Clinical characteristics
Severity of depressive symptoms was measured with the
30-item Inventory of Depressive Symptomatology (IDS,
(Rush et al., 1996)). Severity of anxiety symptoms was
measured using the 15-item Fear Questionnaire (Marks and
Mathews, 1979) and the 21-item Beck Anxiety Inventory
(BAI, (Beck et al., 1988)). Information on duration of
symptoms prior to baseline was derived from LCA (Lyketsos
et al., 1994) at baseline which assessed the percent of time
the patient spent with depressive and/or anxiety symptoms
in the prior four years. Based on CIDI data, the following
speciﬁc types of baseline depressive disorder were differen-
tiated to explore the role of type of disorder: ﬁrst onset MDD,
recurrent MDD, and dysthymia (without MDD). Speciﬁc types
of anxiety disorder included social phobia, generalized
anxiety disorder, panic disorder with or without agoraphobia,
and agoraphobia without panic. Age of onset of the index
disorder was assessed, and earliest age was used for those
with comorbid disorders. A history of a remitted depressive or
anxiety disorder – other than the index disorder – before
baseline was determined in the CIDI interview. The presence
of a family history of depression or anxiety among ﬁrst degree
relatives (not including offspring) was determined using the
family tree method (Fyer and Weissman, 1999). Comorbidity
of alcohol use disorderswas determined using lifetime DSM-IV
diagnoses in the CIDI interview. An indicator for care setting
differentiated subjects receiving specialized mental health
care vs those receiving care from general practitioners, the
gatekeeper for care to Dutch citizens. Medication use was
assessed based on drug container inspection of drugs used in
the past month and coded using the Anatomical Therapeutic
Chemical (ATC) classiﬁcation. Use of antidepressants was
considered when taken at least 50% of the time and included
selective serotonin reuptake inhibitors (ATC-code N06AB),
tricyclic antidepressants (N06AA) and other antidepressants
(N06AF/N06AX). The receipt of psychological treatment
(either formal psychotherapy or counseling as well as skills
training) was based on self-reported information.
2.4. Statistical analyses
Characteristics and 2-year course outcomes were com-
pared across baseline diagnostic status (Dep, Anx, Comorb)
using chi-square statistics for categorical variables and
analyses of variance for continuous variables. Time to
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were compared using Mann Whitney tests because of the
non-normal distributions of these outcomes. The cumulative
probability of ﬁrst remission was estimated with Kaplan–
Meier product limit and survival curves were compared
across baseline diagnostic groups using the log-rank test.
Subjects with a duration greater than 24 months were
censored at 24 months. Median survival time is the ﬁrst
recovery at which cumulative survival reaches 50%.
Subsequently, associations between sociodemographic
and clinical factors with 2-year course were examined.
Using Cox's proportional hazards analyses univariate and
multivariate (adjusted for other covariates) associations
between sociodemographic and clinical factors with time to
ﬁrst remission were examined. Logistic regression analyses
determined associations with a 2-year diagnostic status.
Finally, multivariate associations with the 4-category course
trajectory indicator were determined in multinomial logistic
regression analyses using early remission as the reference
group and calculating risks for the outcome late remission,
remission with recurrence and chronic course. As an overall
indication of the ability to discriminate between patientswith
and without poor course outcome based on ﬁnal multivariate
models, the concordance-statistic (c-statistic, i.e. the area
under the Receiver Operating Characteristic curve) was
calculated. C-statistics between 0.7 and 0.8 are generally
considered as acceptable and between 0.8 and 0.9 as excellent
(Hosmer and Lemeshow, 2000).
3. Results
The study sample mean age was 42.1 years, and 66.0% was
female. Of all 1209 participants, 39.1% received medication
and 44.0% received psychological treatment at baseline
(38.3% received no treatment at all, 40.3% received one and
21.4% received both forms of treatment). The index episodes
of the Comorbid group were more severe and protracted and
this group reported an earlier age of onset and more often
receiving treatment (Table 1).
3.1. 2-year course of anxiety and depressive disorders
Themajority of persons with depressive disorder remitted
within 2 years: 79.5% of the Dep group and 74.5% of the
Comorbid group (Table 2). Although these percentages did
not differ, median time to remission was signiﬁcantly shorter
in the Dep group (6 months) than in the Comorbid group
(12 months). Among depressed subjects who remitted, 22%
developed a recurrent episode during follow-up. Recurrence
rate was similar for the Dep and Comorbid groups.
Remission from anxiety disorder showed a less favorable
picture: only 58.7% from the Anx group and 50.4% from the
Comorbid group remitted, and median remission time was
much higher than for depressive disorder: 16 months for Anx
and 24 months for Comorbid. Among those who remitted,
recurrence rates were comparable to those found for
depression: 21.9% for Anx and 23.8% for Comorbid.
Time to ﬁrst remission of the index disorder was
signiﬁcantly different for the Dep, Anx and Comorbid groups
(log-rank pb .001, Fig. 1). For the Comorbid group, this was
deﬁned as remission when both anxiety and depression hadremitted. Since a symptom-free period of 3 months was
deﬁned as remission, ﬁrst remissions could only occur at
4 months of follow-up. Half of the Dep group recovered
within 6 months, which was 16 months in the Anx group.
Over 2 years, less than half of the Comorbid group (44%) had
recovered from both anxiety and depression.
Looking at psychiatric status at two-year follow-up, 47.6%
and 46.0% of the Dep and Anx groupswerewithout a disorder,
whichwas only 25.1% in the Comorbid group (pb .001). Of the
Dep group, 7.5% switched to anxiety and 16.1% developed
anxiety comorbid to a sustained depression. Results in the
Anx group were very similar: 7.0% switched to depression
and 16.4% developed comorbid depression.
Using the clinical course trajectory indicator combining
data on depression and anxiety symptoms, chronic course
without remission was least common in the Dep group
(24.5%), and most common among the Comorbid group
(56.8%, pb .001), with the Anx group in an intermediate
position (41.9%). This is further conﬁrmed by the continuous
symptom duration indicator from the LCA. The median
percentage of time during follow-up with anxiety or
depression symptoms was 38% in the Dep group, 63% in the
Anx group and 92% in the Comorbid group (pb .001).
3.2. Determinants of 2-year course
Determinants of time to ﬁrst remission of depression and/or
anxiety were analyzed using Cox's survival analyses (Table 3).
Univariately, both Anx and Comorbid groups showed a signiﬁ-
cantly lower risk for ﬁrst remission – indicating a longer episode
duration – as compared to the Dep group. Additional indicators
associatedwith lower risk forﬁrst remissionwereﬁrst compared
to recurrent MDD, panic disorder compared to GAD or
agoraphobia, longer baseline symptom duration, higher symp-
tom severity, early age of onset, no personal history of a remitted
other depressive or anxiety disorder, and being in the mental
health care setting or receiving treatment. In a multivariate
model, seven predictors remained signiﬁcant: pure anxiety and
comorbid depression–anxiety as compared to pure depression,
older age, longer baseline duration of the index disorder, earlier
age of onset, more severe fear symptoms and no earlier personal
(remitted) history were independently associated with lower
risk to ﬁrst remission. Trends were observed for more severe
depressive symptoms with lower risk to ﬁrst remission, and
having agoraphobia with higher risk to ﬁrst remission. The c-
statistic of the ﬁnal multivariate model was 0.73, indicating a
reasonable discriminative ability in predicting ﬁrst remission.
When examining the presence of a depressive or anxiety
disorder (6-month recency) after two years using logistic
regression analyses, a very similar picture of predictors emerged
(Table 3). Comorbidity, longer symptomduration at baseline and
more severe depressive and fear symptoms independently
predicted the presence of disorders after two years. In addition,
agoraphobia was associated with a better outcome, while older
age and early age of onset were associated with worse outcome.
The c-statistic of theﬁnalmodelwas 0.72, indicating a reasonable
discriminative ability.
When examining determinants of the 4-category clinical
course trajectory outcome inmultinomial regression analyses
(Table 4), again worse outcome was more likely to occur in
the Anx and Comorbid groups (as compared to the Dep
Table 1
Baseline characteristics according to baseline psychiatric status (n=1209).
Pure depression
N=267
Pure anxiety
N=487
Comorbid depression–anxiety
N=455
p a
Sociodemographics
Age (mean years, SD) 42.2 (12.7) 41.8 (12.6) 42.3 (11.9) .82
Sex,% female 63.7% 68.2% 65.1% .40
Education (mean years, SD) 12.0 (3.2) 12.2 (3.3) 11.1 (3.2) b.001
Clinical psychiatric characteristics
Type of baseline disorder:
First episode of MDDk 39.3% – 49.2%
Recurrent MDD 56.6% – 44.6%
Dysthymia 20.6% – 37.1%
Panic disorder – 47.2% 50.1%
Social phobia – 50.1% 53.4%
Generalized anxiety disorder – 22.2% 48.8%
Agoraphobia (without panic) – 17.0% 13.0%
Number of anxiety disorders (mean, SD) – 1.4 (0.6) 1.6 (0.7)
Duration of symptoms at baseline:
% months with symptoms in past 4 years 42.2 (30.1)% 57.8 (37.6)% 66.7 (32.5)% b.001
Severity of symptoms at baseline:
Inventory of Depressive Symptoms (score, SD) 30.7 (10.5) 23.4 (9.9) 37.2 (10.8) b.001
Beck Anxiety Inventory (score, SD) 13.6 (8.8) 15.6 (9.5) 22.3 (10.7) b.001
Fear Questionnaire (score, SD) 23.8 (17.2) 33.4 (18.3) 40.6 (21.4) b.001
Personal history of other remitted depressive or anxiety disorder 39.7% 67.8% 28.6% b.001
Family history of depression or anxiety 82.4% 83.5% 86.8% .21
Comorbid alcohol use disorder 29.6% 29.8% 32.7% .54
Age of onset:
Age on onset (mean years, SD) 25.4 (13.1) 19.9 (11.8) 19.5 (12.5) b.001
Care setting:
Primary care 41.6% 54.0% 34.9% b.001
Specialized mental health care 58.4% 46.0% 65.1%
Psychiatric treatment at baseline
Medication 38.2% 30.4% 49.0% b.001
Psychological treatment 43.8% 37.8% 50.8% b.001
a p-value based on chi-square statistics for categorical variables and analyses of variance for continuous variables.
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Agoraphobia was associated with a more favorable course.
Independent of differences in severity, duration and comor-
bidity across settings — the course of patients treated in
specialized mental health care was worse than that in
primary care, and was worse for those with an earlier age of
onset. Persons with an earlier history of another remitted
disorder had a lower risk of a chronic course. The c-statistic of
the multivariate model was high for the chronic course
outcome (c=0.77) indicating that the discriminative ability
of the ﬁnal model was good.
4. Discussion
This study described and compared the 2-year diagnostic
and symptom trajectory outcome of depressive and anxiety
disorders in a large naturalistic cohort of subjects from both
primary and specialized mental health care settings. Its
results – using similar measurements allowing for direct
comparison – clearly indicate that anxiety disorders have a
longer time to ﬁrst remission and a more chronic course
trajectory than depressive disorders. For example, themedian
episode duration to ﬁrst remission was 6 months for the Dep
group and 16 months for the Anx group, whereas a chronic
course of symptoms was present in 24.5% and 41.9%,
respectively. An even more distinctive group in terms of
both the diagnostic and symptom trajectory outcomes werethose with comorbid depression–anxiety: their median
episode duration was over 24 months and 55.3% developed
a chronic course. The most consistent independent predictors
of poor diagnostic or symptom trajectory outcomes were
comorbid depression–anxiety, severity and duration of the
index episode, early age of onset, and older age. A model
based on these very basic sociodemographic and clinical
prognostic factors showed quite reasonable discriminative
ability to the course outcome over 2 years.
Compared to prior population-based studies or inception
cohorts reporting episode durations between 3 and 4 months
(Furukawa et al., 2000; Keller et al., 1992; Spijker et al., 2002)
our median episode duration of depression is in the higher
range, but results are in line with those from other clinical
population studies (Ormel et al., 1993; Solomon et al., 1997;
Tiemens et al., 1996). Also the ﬁnding that about 80% of the
depressed subjects reach remission within 2 years is in line
with earlier ﬁndings (Ormel et al., 1993). For anxiety
disorders, the observed 46% without a disorder after two
years, is in line with the reported 48% among social phobia
patients in the HARP study (Keller, 2006). Time to ﬁrst
complete remission for subjects with comorbid depression–
anxiety has not been clearly described before. Our ﬁndings
indicate that the median episode duration for comorbid
subjects is extensive, as it stretches beyond the 24 months.
We did not ﬁnd evidence for extensive diagnostic
‘instability’ across depression and anxiety disorders, as
Table 2
Two-year course indicators according to baseline psychiatric status (N=1209).
Pure depression
N=267
Pure anxiety
N=487
Comorbid depression–anxiety
N=455
p a
Remission from depressive disorder
Depression remission 79.5% NA 74.5% .13
Median time to remission, in months (IQR) 6.0 (18.0) NA 12.0 (20.0) .01
Among those with remission:
Recurrence of depression 21.5% NA 22.3% .83
Median time to recurrence, in months (IQR) 6.0 (6.0) NA 5.0 (5.0) .06
Remission from anxiety disorder
Anxiety remission NA 58.7% 50.4% .01
Median time to remission, in months (IQR) NA 16.0 (20.0) 24.0 (20.0) .03
Among those with remission:
Recurrence of anxiety NA 21.9% 23.8% .62
Median time to recurrence, in months (IQR) NA 4.0 (5.0) 4.0 (9.0) .28
Psychiatric status after 2 years b.001
No depressive or anxiety disorder 47.6% 46.0% 25.1%
Depressive disorder 28.8% 7.0% 15.2%
Anxiety disorder 7.5% 30.6% 20.2%
Depressive and anxiety disorder 16.1% 16.4% 39.6%
Clinical course trajectory of combined depression and anxiety symptoms b.001
Early remission (≤6 months) 34.7% 29.3% 14.0%
Late remission (N6 months) 15.1% 11.8% 13.5%
Remission with recurrence 25.7% 17.1% 15.8%
Chronic course without remission 24.5% 41.9% 56.8%
Duration of symptoms during follow-up
Percent time (median, IQR) with depression 32 (68) 0 (12) 50 (72) b.001
Percent time (median, IQR) with anxiety 0 (12) 60 (89) 80 (89) b.001
Percent time (median, IQR) with depr. or anx. 38 (76) 63 (84) 92 (57) b.001
IQR = interquartile range.
a p-value based on chi-square statistics for categorical variables and Mann Whitney non-parametric statistics for continuous variables.
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pure depression group switched to an anxiety disorder over
2 years, which was similar to the corresponding switch from
anxiety to depression. It is interesting to point out that pure
depression and anxiety groups did not differ signiﬁcantly in
terms of diagnostic status after 2 years: about 47% was
diagnosis-free. This ﬁnding illustrates that it can be mislead-
ing to limit focus on diagnostic status alone, since one then
wrongly would have concluded that prognosis was similar.
Integrating the in-between symptomatology – as in the
present study – showed that the 2-year course trajectory was1
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Fig. 1. Survival curve illustrating time until ﬁrst remission across baseline
psychiatric status (n=1209). The dotted lines (........) are projected lines
since by deﬁnition no remission could have occurred within the ﬁrst 3-
month period.different: anxiety patients reported longer episode duration,
more time with symptoms and a more chronic course than
depressed patients.
With regard to prognostic factors, demographics were not
consistently among the most important predictors. Although
female gender and low education have shown to predict
onset of anxiety and depression (Bijl et al., 1998a; Kessler
et al., 1994; Seedat et al., 2009), our ﬁndings indicate that
they are not as important in determining prognosis. Older age
predicted poorer course outcome over 2 years, which is in
line with studies suggesting that the course of depression in
old age may be less favorable than that of younger adults
(Licht-Strunk et al., 2009). Clinical characteristics were
clearly the most important predictors of the ensuing
prognosis. Consistent determinants were severity and dura-
tion of the index episode and comorbid depression–anxiety. It
is important to emphasize that these predictive factors
exerted their effect independent of each other. In other
words, the poorer course outcomes among comorbid patients
remained after controlling for baseline differences in severity
and duration of symptoms. The reason why the comorbid
group has such an unfavorable prognosis remains to be
uncovered and may be sought in both the genetic and
environmental realms. Another interesting ﬁnding was that a
history of an earlier remitted disorder – other than the index
disorder – predicted an earlier remission and a lower risk of
chronic course. This could be explained by the fact that those
with remissions in the past may identify persons who suffer
more from intermittent course trajectories characterized by
rather unstable, short-termed and switching conditions.
Table 3
Univariate and multivariate determinants of time to ﬁrst remission (episode duration) and presence of a depressive or anxiety disorder at 2-year follow-up
(N=1209).
Time to ﬁrst remission of depression and/or
anxiety disorder
Presence of a depressive or anxiety disorder
at 2-year follow-up
Univariate a Multivariate a Univariate b Multivariate b
RR (95% CI) RR (95% CI) RR (95% CI) RR (95% CI)
Baseline psychiatric status
Pure depression Ref Ref Ref Ref
Pure anxiety 0.66 (0.55–0.79) ‡ 0.68 (0.51–0.89) ‡ 1.07 (0.79–1.44) 1.13 (0.71–1.79)
Comorbid depression–anxiety 0.43 (0.35–0.52) ‡ 0.60 (0.46–0.77) ‡ 2.71 (1.97–3.74) ‡ 1.70 (1.11–2.55) ‡
Sociodemographics
Age (per 10 years increase) 0.96 (0.90–1.02) 0.92 (0.86–0.99) ‡ 1.09 (0.99–1.19) † 1.16 (1.03–1.31) ‡
Female gender 1.13 (0.96–1.33) 1.12 (0.95–1.33) 1.01 (0.79–1.30) 1.07 (0.80–1.42)
Education (per year increase) 1.02 (1.00–1.04) † 1.00 (0.97–1.02) 0.97 (0.94–1.01) † 1.03 (0.98–1.07)
Speciﬁc psychiatric indicators
Type of depressive disorder
First episode MDD Ref Ref Ref Ref
Recurrent MDD 1.29 (1.05–1.58) ‡ 1.05 (0.85–1.36) 0.78 (0.56–1.08) 0.98 (0.68–1.40)
Dysthymia 1.09 (0.69–1.71) 0.99 (0.62–1.58) 0.78 (0.39–1.56) 0.85 (0.40–1.81)
Type of anxiety disorder
Panic disorder Ref Ref Ref Ref
Social phobia 0.97 (0.78–1.21) 0.93 (0.74–1.16) 0.78 (0.57–1.06) 0.79 (0.56–1.13)
GAD 1.32 (1.02–1.72) ‡ 1.21 (0.92–1.60) 0.65 (0.44–0.98) ‡ 0.75 (0.47–1.17)
Agoraphobia (without panic) 1.54 (1.14–2.10) ‡ 1.35 (0.98–1.85) † 0.38 (0.23–0.63) ‡ 0.55 (0.32–0.94) ‡
Symptom duration at baseline
Per 10% duration increase 0.91 (0.89–0.93) ‡ 0.94 (0.92–0.97) ‡ 1.14 (1.10–1.18) ‡ 1.08 (1.04–1.13) ‡
Severity of symptoms
IDS (per SD increase) c 0.79 (0.73–0.85) ‡ 0.90 (0.80–1.02) † 1.89 (1.65–2.16) ‡ 1.41 (1.15–1.72) ‡
BAI (per SD increase) c 0.78 (0.72–0.85) ‡ 0.97 (0.87–1.09) 1.72 (1.51–1.97) ‡ 1.11 (0.92–1.33)
Fear Q (per SD increase) c 0.75 (0.69–0.81) ‡ 0.90 (0.82–0.99) ‡ 1.74 (1.52–1.98) ‡ 1.29 (1.10–1.51) ‡
Age of onset
Per 10 years increase 1.12 (1.06–1.18) ‡ 1.08 (1.00–1.16) ‡ 0.84 (0.77–0.92) ‡ 0.87 (0.77–0.98) ‡
Personal history of other remitted
depressive or anxiety disorder
1.27 (1.09–1.47) ‡ 1.33 (1.12–1.57) ‡ 0.84 (0.67–1.06) 0.92 (0.69–1.22)
Family history depression/anxiety 0.96 (0.78–1.18) 0.97 (0.79–1.09) 1.06 (0.77–1.46) 0.91 (0.64–1.29)
Comorbid alcohol use disorder 0.91 (0.77–1.08) 0.98 (0.82–1.16) 1.32 (1.02–1.70) ‡ 1.26 (0.95–1.69)
Care setting:
Primary care Ref Ref Ref Ref
Mental health care 0.79 (0.68–0.92) ‡ 0.90 (0.75–1.09) 1.53 (1.21–1.93) ‡ 1.17 (0.86–1.61)
Treatment
Medication 0.85 (0.73–0.99) ‡ 0.98 (0.82–1.16) 1.38 (1.09–1.76) ‡ 0.96 (0.72–1.28)
Psychological treatment 0.92 (0.79–1.07) 1.00 (0.84–1.18) 1.29 (1.02–1.63) ‡ 1.06 (0.80–1.40)
C-statistic (95% CI) 0.73 (0.70–0.76) 0.72 (0.69–0.75)
‡ pb .05, † pb .10.
a Based on Cox's proportional survival analyses.
b Based on logistic regression analyses.
c SD for IDS=12.3, SD for BAI=10.4, SD for Fear Q=20.1.
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bia without panic had a more favorable course than those
with panic disorder or other anxiety patients. This is
consistent with the idea that agoraphobia alone may identify
persons with rather mild anxiety. In addition, earlier age of
onset increased the risk of poor course, which adds to the
recent suggestion (Kendler et al., 2009) that early onset
disorders typify a subset of patients with a distinct etiological
proﬁle in which genetic vulnerability and early developmen-
tal aspects play a larger role. Our study adds that early onset
disorders – apart from severity and duration – seem to result
in poorer prognosis as well.
With regard to treatment setting, in most multivariate
analyses adjusting for differences in severity, duration and
other clinical aspects, course differences between patients in
primary vs specialized mental health care did not retain.
However, for the late recovery and chronic course outcomesthose in the mental health care setting remained to have a
signiﬁcantly higher risk. This may indicate that additional
underlying differences – such as care seeking behavior
(Verhaak et al., 2009) or personality (Spinhoven et al.,
2009) – across treatment settings may exist and play a role
in course prediction. Although signiﬁcant in univariate
analyses, treatment was not a signiﬁcant course determinant
anymore in multivariate analyses containing clinical infor-
mation on e.g. severity and duration of symptoms, as found
before (Ormel et al., 1993; Spijker et al., 2002). This, however,
does not imply that treatment is unimportant. Treatmentmay
well inﬂuence the course of the disorders, but since clinical
indicators also determine receipt of treatment, an observa-
tional study may end up ﬁnding no association. Only
experimental studies can examine the effect of treatment.
Using basic sociodemographic and clinical indicators, we
were able to achieve a reasonable discriminative ability to
Table 4
Multivariate a determinants of the clinical course trajectory of depressive and anxiety symptoms (N=1209).
Late remission
(vs early remission)
Remission+recurrence
(vs early remission)
Chronic course
(vs early remission)
RR (95% CI) RR (95% CI) RR (95% CI)
Baseline psychiatric status
Pure depression Ref Ref Ref
Pure anxiety 0.74 (0.39–1.40) 1.10 (0.53–2.26) 2.57 (1.34–4.75) ‡
Comorbid depression–anxiety 0.48 (0.26–0.87) ‡ 1.28 (0.68–2.40) 2.22 (1.26–3.82) ‡
Sociodemographics
Age (per 10 years increase) 1.16 (0.97–1.38) † 0.93 (0.77–1.12) 1.15 (0.99–1.34) †
Female gender 0.72 (0.48–1.07) 1.13 (0.72–1.78) 0.77 (0.53–1.11)
Education (per year increase) 1.07 (0.95–1.07) 1.00 (0.93–1.06) 1.00 (0.95–1.06)
Speciﬁc psychiatric indicators
Type of depressive disorder
First episode MDD Ref Ref Ref
Recurrent MDD 0.90 (0.54–1.51) 1.73 (1.03–2.96) 1.18 (0.74–1.82)
Dysthymia 0.42 (0.12–1.49) 1.17 (0.39–3.53) 1.04 (0.41–2.62)
Type of anxiety disorder
Panic disorder Ref Ref Ref
Social phobia 0.95 (0.54–1.64) 1.51 (0.86–2.63) 1.25 (0.79–1.98)
GAD 0.74 (0.37–1.45) 0.95 (0.48–1.84) 0.67 (0.38–1.17)
Agoraphobia (without panic) 0.52 (0.24–1.12) † 0.67 (0.30–1.54) 0.48 (0.28–0.91) ‡
Symptom duration at baseline
Per 10% duration increase 1.02 (0.96–1.08) 1.01 (0.95–1.08) 1.12 (1.07–1.18) ‡
Severity of symptoms
IDS (per SD increase) b 1.37 (1.03–1.83) † 1.34 (0.99–1.82) † 1.48 (1.15–1.92) ‡
BAI (per SD increase) b 0.82 (0.62–1.07) 0.82 (0.61–1.09) 0.92 (0.73–1.16)
Fear Q (per SD increase) b 1.23 (0.97–1.55) † 1.38 (1.08–1.76) ‡ 1.35 (1.10–1.65) ‡
Age of onset
Per 10 years increase 0.89 (0.75–1.05) 0.97 (0.80–1.17) 0.82 (0.71–0.96) ‡
Personal history of other remitted depressive or anxiety disorder 0.82 (0.55–1.23) 1.11 (0.72–1.71) 0.56 (0.39–0.80) ‡
Family history depression/anxiety 1.09 (0.67–1.78) 1.02 (0.60–1.74) 1.08 (0.69–1.69)
Comorbid alcohol use disorder 0.94 (0.62–1.42) 1.10 (0.71–1.71) 1.08 (0.74–1.56)
Care setting
Primary care setting Ref Ref Ref
Mental health care setting 1.79 (1.14–2.81) ‡ 1.08 (0.67–1.73) 1.56 (1.05–2.33) ‡
Treatment
Medication 1.06 (0.70–1.61) 0.95 (0.61–1.47) 1.04 (0.72–1.50)
Psychological treatment 0.73 (0.48–1.10) 1.38 (0.89–2.12) 0.96 (0.66–1.38)
C-statistic (95% CI) 0.69 (0.65–0.74) 0.71 (0.65–0.76) 0.77 (0.74–0.81)
‡ pbb .05, † pbb .10.
a Based on multinomial logistic regression analyses.
b SD for IDS=12.3, SD for BAI=10.4, SD for Fear Q=20.1.
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chronic course trajectory: c-statistics were 0.72, 0.73 and
0.77, respectively. Reﬁnement and validity checks of a risk
proﬁle for course prediction were beyond the scope of this
study, but deserve further research. The development of such
a risk proﬁle is never based on one single study, and the
effects of implementing such a risk proﬁle in clinical practice
should be tested in further research. However the ingredients
that deserve consideration in such a risk proﬁle become
apparent: our ﬁndings illustrate that – although there is some
room for improvement – rather simple clinical characteristics
provide good tools to identify people at risk for a poor
outcome.
The present study included prevalent depression and
anxiety cases as they were residing in primary care or when
newly enrolled in specializedmental health care. Their course
may not be directly comparable (and is likely somewhatmore
severe) to that of incident cases. Nevertheless, the clinical
reality is that presenting patients often already have a history
of symptoms, so our ﬁndings are generalizable to standard
clinical settings. In addition, although longer-term follow-upprovides more information on episode and symptom recur-
rence beyond 2 years, it is known that the largest course
variation takes place within this time period. Study strengths
are its large well diagnosed sample from primary and
specialized mental care settings in which we applied both a
diagnostic and a symptom trajectory approach.
Our ﬁndings have several potential clinical implications.
First, they support the importance of a full diagnostic
approach covering the entire depressive and anxiety spec-
trum since this provides useful predictive information.
Second, they suggest that rather simple clinical characteris-
tics provide good tools for course prediction. Third, they lend
support for individualized care approaches in which the least
intensive treatment strategies (e.g. watchful waiting) are
provided to those at lowest chronicity risk reserving more
intensive treatment strategies (e.g. combinedmedication and
psychotherapy) for those at the highest chronicity risk.
Although such individualized treatment approaches have
clear face value, future research should evaluate whether
such ‘stepped care approaches’ in clinical practice are indeed
effective. Our ﬁndings indicate that based on various rather
84 B.W.J.H. Penninx et al. / Journal of Affective Disorders 133 (2011) 76–85simple clinical characteristics it appears possible to predict
the course risk of individual patients.
In sum, our ﬁndings indicate that pure anxiety had amuch
longer time to ﬁrst remission and a more chronic symptom
trajectory than pure depression. Depression–anxiety comor-
bidity results in even more persistence of diagnostic and
symptom trajectory outcomes. Their differential course
trajectory justiﬁes separate consideration of pure depression,
pure anxiety and comorbid anxiety–depression in clinical
practice and psychiatric nosology.
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